Australia/USA – Mesoblast Secures FDA Orphan-Drug Exclusivity for RYONCIL
Regulatory Achievement Overview Mesoblast has obtained seven years of orphan-drug exclusive approval from FDA for RYONCIL® (remestemcel-L) in treating steroid-refractory acute graft versus host...
